|Day Low/High||147.50 / 151.82|
|52 Wk Low/High||114.53 / 199.43|
We are keeping with our "buy the bullets, not the guns" strategy.
Doug Kass shares his thoughts on the deepening of retail stocks' weakness and the Amazon Effect.
McKesson Corporation (NYSE:MCK) will release financial results for its third fiscal quarter, ended December 31, 2016, on Wednesday, January 25, 2017, following market close at approximately 4:00 PM Eastern Time (1:00 PM...
Apple, Energen and McKesson are among the top stock picks of Mizuho's analysts for 2017.
McKesson Corporation (NYSE:MCK), a leading international healthcare services and information technology company, announced today that it has completed the previously announced acquisition of Rexall Health for $2.
McKesson Corporation (NYSE:MCK), a leading global healthcare services and information technology company, and Change Healthcare Holdings, Inc.
McKesson Corporation (NYSE:MCK) today announced that John Hammergren, chairman and chief executive officer, will present at the 35 th Annual J.
Doug Kass shares his thoughts on divergences in the market's armor and observes that real tech regulation is complicated.
The charts for Cerner, Eli Lilly and McKesson do not flash buy signals.
McKesson Corporation (NYSE: MCK) today announced that it has signed a consent agreement with the Competition Bureau of Canada allowing it to proceed with the acquisition of Rexall Health (inclusive of Rexall/Pharma Plus,...
Cerner, Eli Lilly and McKesson are three health care companies that are trading at a bargain.
Current valuations are at record lows, despite the companies having good prospects.
Here are Wednesday's top research calls, including downgrades for Abercrombie & Fitch, CBS and McKesson, and an upgrade for Analog Devices.
Since the election, big questions remain about investing in hospital and healthcare stocks, and the group will remain volatile according to Mizuho.
Doug Kass shares his thoughts on closed-end municipal bond funds.
Doug Kass shares his thoughts on the bond market's bounciness and stocks suffering election uncertainty.
Cramer shares his views on the rise of the stay-at-home consumer. Starbucks, Apple and Facebook are among the stocks discussed.
Cramer shares his views on price war victims. Nike, Allergan and Netflix are among the stocks discussed.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ANH, CCRN, CPE, DVCR, ESRT, LBRDA, LBRDK, MIXT, MTGE, ORN, PWR, ROG, TTWO, TWO, USCR Downgrades: AGU, ARC, CHTR, DPLO, EGN, ELY, F, FOMX, GNE, GTN.A, GTS, MCK, SIRI, THS, XOXO, ZEUS Initiations: KHC Read on to get TheStreet Quant Ratings' detailed report:
Stocks in the health care sector seem to have no underpinnings whatsoever.
Shares are trading at less than 12.5x 2017's EPS estimates and should rise soon.
Investors rush to buy the drugmaker's stock following chatter of a much-needed megadeal.
Today there was a virtual vacuum of good news in the stock market.
Jim Cramer says there are other reasons not to buy Valeant, other than the criminal investigation.
Pfizer shares were slipping after the drugmaker posted a premarket earnings whiff.
Valeant shares drop as regulators investigate possible accounting fraud.